Buy Ivermectin for Humans Online, Ivermectin (Stromectol)

---

Generic Name: Ivermectin (Generic Stromectol®)
Brand Names: Stromectol, Soolantra, Sklice
Known as: Mectizan
Price: from $ 1.75 per pill
Dosages: 12 mg, 6 mg, 3 mg
FDA Approved Uses: Worm Infections and other parasites


Order Ivermectin Now

---

Content

• The History of Ivermectin

• Mechanism of Action

• Approved Uses of Ivermectin

  • Treatment of Parasitic Infections

  • Scabies and Head Lice

  • Veterinary Applications

• Emerging Uses of Ivermectin

• Controversies and Misuse

  • Ivermectin and COVID-19

  • Self-Medication and Veterinary Use

  • Misinformation and Polarization

• Risks and Side Effects

• Ivermectin in the Context of Global Health

• Future Directions

• Transition to Human Medicine

• The Bottom Line

• Q & A About Ivermectin

---

Ivermectin (Stromectol)

---

Medically Reviewed by Gargi Gharat, PA-C, MMS, Foreign MD | Written by Keisha Vatel | Published 01/16/2022 | Updated 02/04/2025

---

Ivermectin (Stromectol), a drug that has been in use for over four decades, has garnered widespread attention for its versatility and effectiveness against various parasitic infections. Originally developed for veterinary medicine, ivermectin has transformed into a groundbreaking medication for human use. Despite its immense success in combating parasitic diseases, ivermectin’s journey has not been without controversy. This article delves into the history, applications, mechanisms, benefits, risks, and debates surrounding ivermectin.

The History of Ivermectin

Ivermectin was discovered in the late 1970s by Japanese microbiologist Satoshi Ōmura and American parasitologist William C. Campbell. Derived from a naturally occurring bacterium, Streptomyces avermitilis, ivermectin was initially intended for veterinary use to combat parasitic infections in animals.

In 1987, the pharmaceutical company Merck introduced ivermectin for human use under the brand name Mectizan. It quickly gained acclaim for its role in eradicating river blindness (onchocerciasis) and lymphatic filariasis in endemic regions, particularly in sub-Saharan Africa and Latin America. The significance of these efforts earned Ōmura and Campbell the 2015 Nobel Prize in Physiology or Medicine.

Mechanism of Action

Ivermectin works by targeting the nervous systems of parasites. It binds to specific ion channels known as glutamate-gated chloride channels, which are present in the nerve and muscle cells of many invertebrates. By enhancing the influx of chloride ions, ivermectin causes paralysis and death of the parasite.

The specificity of ivermectin’s action minimizes harm to mammals, as these channels are absent in human physiology. Additionally, ivermectin affects other channels, such as gamma-aminobutyric acid (GABA)-gated channels, though its affinity for these is much lower in humans, further reducing toxicity risks.

Approved Uses of Ivermectin

1. Treatment of Parasitic Infections

• Onchocerciasis (River Blindness): Ivermectin is a cornerstone in the fight against this disease caused by the parasitic worm Onchocerca volvulus.

• Lymphatic Filariasis: Administered as part of mass drug administration programs to halt the transmission of the Wuchereria bancrofti and Brugia species.

• Strongyloidiasis: Effective against Strongyloides stercoralis, a parasitic nematode causing gastrointestinal and systemic infections.

2. Scabies and Head Lice

Ivermectin has been widely used to treat ectoparasites, such as Sarcoptes scabiei (scabies) and head lice. Its oral administration has proved particularly beneficial for patients with severe or crusted scabies.

3. Veterinary Applications

• Control of parasitic infections in livestock and pets, including heartworm and gastrointestinal nematodes.

• Used as an antiparasitic for horses, cattle, sheep, and dogs.

Emerging Uses of Ivermectin

While ivermectin is primarily known for its antiparasitic properties, recent research has explored its potential in addressing other conditions, including:

1. Antiviral Properties

Laboratory studies have indicated that ivermectin exhibits antiviral effects against several viruses, including Zika, Dengue, and HIV. These findings have sparked interest in its role as a potential broad-spectrum antiviral agent.

2. Inflammatory Disorders

Preliminary research suggests that ivermectin might have anti-inflammatory effects, making it a candidate for conditions like rosacea.

Controversies and Misuse

1. Ivermectin and COVID-19

The COVID-19 pandemic brought ivermectin into the spotlight as a purported treatment for SARS-CoV-2. Despite limited initial studies suggesting antiviral properties, subsequent large-scale trials did not conclusively support its efficacy against COVID-19.

Regulatory agencies such as the FDA, WHO, and EMA advised against its use for COVID-19 outside of controlled clinical trials. However, misinformation and advocacy by some groups led to widespread off-label use, particularly in regions with limited access to vaccines or proven treatments.

Arguments for Ivermectin

Proponents of ivermectin as a COVID-19 treatment argue:

• Preclinical Studies: Laboratory evidence showed antiviral activity.

• Anecdotal Success: Some healthcare providers reported positive outcomes in patients treated with ivermectin.

• Low Cost and Accessibility: Advocates highlighted its affordability, particularly in low-income countries.

Criticism and Lack of Evidence

Critics and major health organizations, including the WHO, FDA, and CDC, raised concerns about the lack of robust evidence supporting ivermectin's efficacy against COVID-19. Issues included:

• Small Sample Sizes: Many studies were underpowered.

• Methodological Flaws: Poorly designed trials and potential biases.

• Inappropriate Dosing: Some proponents recommended doses far exceeding approved levels, raising safety concerns.

2. Self-Medication and Veterinary Use

One of the most significant concerns has been the misuse of ivermectin products designed for animals. Veterinary formulations, which contain much higher doses, were consumed by individuals attempting to self-treat COVID-19, leading to numerous cases of toxicity.

3. Misinformation and Polarization

The debate over ivermectin’s role in COVID-19 treatment became highly polarized, with proponents and detractors often clashing in public forums. The ivermectin debate was exacerbated by misinformation on social media. This polarization highlighted broader issues of scientific communication and public trust during the pandemic.

Risks and Side Effects

Ivermectin is generally considered safe when used as prescribed. However, adverse effects can occur, particularly when taken inappropriately or in excessive doses.

Common Side Effects:

• Nausea and vomiting

• Dizziness

• Rash or itching

Severe Reactions:

• Neurotoxicity, including confusion, seizures, and ataxia, in cases of overdose

• Allergic reactions, especially in patients with high parasite loads (Mazzotti reaction)

Overuse and Misuse:

Misuse of ivermectin, particularly in doses meant for animals or as an unapproved COVID-19 treatment, has led to adverse effects such as:

• Neurological symptoms (confusion, seizures).

• Severe liver damage.

• Allergic reactions.

Public health campaigns emphasize the importance of adhering to approved medical guidelines.

Contraindications:

• Not recommended for use in individuals with severe liver or kidney disease.

• Caution advised during pregnancy and breastfeeding.

Ivermectin in the Context of Global Health

Eradication of River Blindness

Ivermectin has been instrumental in reducing the prevalence of river blindness in endemic regions. Mass administration programs supported by Merck’s donation initiative have delivered over 4 billion treatments since 1987.

Improving Livelihoods

By combating parasitic infections in both humans and livestock, ivermectin has significantly improved public health and agricultural productivity, particularly in developing countries.

Addressing Inequalities

Ivermectin's affordability and effectiveness have made it a key tool in addressing health disparities in low- and middle-income countries. The Mectizan Donation Program continues to serve as a model for partnerships between pharmaceutical companies and global health organizations.

Challenges in Access

Despite its success, challenges remain:

• Distribution Logistics: Delivering ivermectin to remote regions.

• Resistance: The potential for parasites to develop resistance to ivermectin.

• Sustainability: Ensuring continued funding and support for donation programs.

Future Directions

Research into Broader Applications

Ongoing research is examining ivermectin’s potential as an antiviral, anti-inflammatory, and even anticancer agent. While promising, these applications require rigorous clinical validation.

• Malaria: Studies suggest it might reduce mosquito transmission.

• Cancer: Preliminary research hints at antiproliferative effects in certain cancers.

• Antiviral Activity: Beyond COVID-19, ivermectin is being investigated for other viral infections.

Addressing Resistance

The emergence of drug-resistant parasites poses a significant challenge. Efforts are underway to develop combination therapies and novel antiparasitic agents to preserve ivermectin’s efficacy.

Education and Regulation

Enhancing public awareness about the appropriate use of ivermectin and ensuring robust regulatory frameworks can mitigate misuse and misinformation.

Challenges in Drug Development

While promising, the development of new ivermectin-based treatments faces hurdles such as:

• Securing funding for large-scale trials.

• Overcoming regulatory hurdles.

• Addressing public skepticism fueled by past controversies.

Transition to Human Medicine

Addressing Neglected Tropical Diseases

The success of ivermectin in animals spurred interest in its potential for human medicine. By the 1980s, ivermectin was approved for treating onchocerciasis (river blindness) in humans. This parasitic disease, caused by Onchocerca volvulus and transmitted by blackflies, devastated communities in sub-Saharan Africa, Latin America, and Yemen.

The Merck Donation Program

Merck, the pharmaceutical company behind ivermectin, launched the Mectizan Donation Program in 1987. This program provided free ivermectin to millions of people in endemic regions. It remains one of the most successful public health initiatives, contributing to significant reductions in river blindness cases.

Broader Human Applications

In addition to river blindness, ivermectin has been approved or used off-label for treating:

• Lymphatic Filariasis: Commonly known as elephantiasis, caused by Wuchereria bancrofti.

• Scabies: A skin condition caused by mites.

• Strongyloidiasis: An intestinal parasitic infection.

• Head Lice: An alternative to topical treatments.

Ivermectin’s broad-spectrum activity and safety profile have made it a valuable tool in combating parasitic diseases.

The Bottom Line

Ivermectin stands as a testament to the potential of science and innovation in transforming public health. From its origins as a veterinary drug to its role in combating neglected tropical diseases, ivermectin has saved millions of lives. However, its controversial use during the COVID-19 pandemic highlights the challenges of navigating scientific uncertainty and public perception.

As research into ivermectin continues, it is essential to rely on rigorous science and ethical practices to unlock its full potential while addressing global health needs responsibly. Whether as a lifesaving antiparasitic or a potential agent in new medical frontiers, ivermectin's journey is far from over.

Q&A About Ivermectin